financetom
Business
financetom
/
Business
/
Why Jaguar Health Stock Is Tanking
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Jaguar Health Stock Is Tanking
May 20, 2024 9:31 AM

Jaguar Health, Inc. ( JAGX ) shares are falling Monday after the company announced a 1-for-60 reverse stock split.

The Details:

The company will effect a reverse stock split at an exchange ratio of 1-for-60, on Thursday, in order to support the company’s compliance with Nasdaq’s listing standards.

“Jaguar’s board of directors has determined that effecting a reverse stock split at this time will, in addition to supporting the Company’s compliance with Nasdaq’s listing standards, provide Jaguar with the opportunity to achieve a share price and outstanding share count that is more attractive to institutional investors,” said Lisa Conte, Jaguar’s CEO.

Last week, Jaguar reported worse-than-expected first-quarter results with losses of 6 cents per share, compared to the losses of 3 cents per share analyst estimate. Quarterly sales also came in below the consensus estimate at $2.351 million. 

Related News: What’s Going On With Faraday Future Stock Today?

JAGX Stock Prediction 2024:

Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.

Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Jaguar Health ( JAGX ), an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Jaguar Health ( JAGX ), the 200-day moving average sits at $0.23, according to Benzinga Pro, which is above the current price of $0.14. For more on charts and trend lines, see a description here.

Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.

JAGX Price Action: According to Benzinga Pro, Jaguar Health ( JAGX ) shares are down 42.5% at 14 cents at the time of publication Monday.

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Blackrock Silver Gets First of Three Key Permits for the Tonopah West Project
Blackrock Silver Gets First of Three Key Permits for the Tonopah West Project
Mar 11, 2026
07:31 AM EST, 03/03/2026 (MT Newswires) -- Blackrock Silver ( BKRRF ) on Tuesday announced the issuance by the Nevada Department of Environmental Protection (NDEP), through the Bureau of Air Pollution Control, the Class II Air Quality and Surface Disturbance Permit for the company's Tonopah West mineral project located along the Walker Lane Trend in Nye and Esmeralda Counties, Nevada,...
EVgo Q4 Loss Narrows, Revenue Rises; 2026 Sales Outlook Set -- Shares Up Pre-Bell
EVgo Q4 Loss Narrows, Revenue Rises; 2026 Sales Outlook Set -- Shares Up Pre-Bell
Mar 11, 2026
07:33 AM EST, 03/03/2026 (MT Newswires) -- EVgo ( EVGO ) reported a Q4 net loss Tuesday of $0.04 per diluted share, compared with a loss of $0.11 a year earlier. Three analysts polled by FactSet expected a loss of $0.07. Revenue for the quarter ended Dec. 31 was $118.5 million, up from $67.5 million a year earlier. Analysts polled...
Cigna names Brian Evanko as CEO
Cigna names Brian Evanko as CEO
Mar 11, 2026
March 3 (Reuters) - Cigna Group ( CI ) said on Tuesday David Cordani would retire as chief executive officer, effective July 1, and be succeeded by Brian Evanko, current president and chief operating officer. ...
Amylyx Pharmaceuticals Q4 Net Loss Narrows
Amylyx Pharmaceuticals Q4 Net Loss Narrows
Mar 11, 2026
07:31 AM EST, 03/03/2026 (MT Newswires) -- Amylyx Pharmaceuticals ( AMLX ) reported a Q4 net loss Tuesday of $0.30 per diluted share, narrower than a loss of $0.55 a year earlier. Three analysts polled by FactSet expected a loss of $0.29. As expected, no revenue for the quarter ended Dec. 31 was reported. As of Dec. 31, the company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved